Get all premium features to the best stock analysis tool

Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio

Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing

The transaction represents the most significant milestone in the company's history.

NEXGEL shareholders will receive a non-dilutive 19.99% equity interest in NexGelRx up to $8 million of capital investment in spin-off

NEXGEL, Inc. ( NXGL ) Q3 2025 Earnings Call November 11, 2025 4:30 PM EST Company Participants Adam Levy - CEO, President & Director Joseph McGuire - Chief Financial Officer Conference Call Participants Valter Pinto - Kanan, Corbin, Schupak & Aronow, Inc. Nazibur Rahman - Maxim Group LLC, Research Division Presentation Operator Good afternoon, everyone. My name is Bo, and I will be your conference operator today.

LANGHORNE, Pa., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its third quarter 2025 financial results for the period ending September 30, 2025.

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.